Mogamulizumab, which is a humanized anti-CCR4, exhibits potent clinical efficacy against CCR4-positive CTCLs and other T cell lymphomas and was shown to efficiently decrease Tregs, leading to CTCL growth inhibition [160]. This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.